Real-World Use of Fingolimod in Patients with Relapsing Remitting Multiple Sclerosis: A Retrospective Study Using the National Multiple Sclerosis Registry in Kuwait

被引：0
|
作者：
Jasem AL-Hashel
Samar F. Ahmed
Raed Behbehani
Raed Alroughani
机构：
[1] Ibn Sina Hospital,Department of Neurology
[2] Kuwait University,Faculty of Medicine
[3] Minia University,Department of Neurology and Psychiatry
[4] Al-Bahar Eye Center,Department of Ophthalmology
[5] Dasman Diabetes Institute,Neurology Clinic
[6] Amiri Hospital,Division of Neurology, Department of Medicine
来源：
CNS Drugs | 2014年 / 28卷
关键词：
Multiple Sclerosis; Expand Disability Status Scale; Natalizumab; Glatiramer Acetate; Fingolimod;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：817 / 824
页数：7
相关论文
共 50 条
  • [31] Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis
    Thomas, Katja
    Proschmann, Undine
    Ziemssen, Tjalf
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1649 - 1660
  • [32] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [33] Predicting response to fingolimod in patients with relapsing-remitting multiple sclerosis
    Giuliani, M.
    Prosperini, L.
    Fanelli, F.
    Hirsch, M. N.
    De Angelis, F.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 306 - 306
  • [34] Real-world safety and patient profile of fingolimod in relapsing-remitting multiple sclerosis: how risky is fingolimod-induced lymphopenia?
    Ozakbas, S.
    Aslan, T.
    Baba, C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 878 - 879
  • [35] Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study
    Zhang, Yao
    Yin, Hexiang
    Zhang, Dingding
    Xu, Yan
    Peng, Bin
    Cui, Liying
    JOURNAL OF NEUROLOGY, 2022, 269 (09) : 4808 - 4816
  • [36] Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study
    Zhang, Y.
    Yin, H.
    Zhang, D.
    Xu, Y.
    Peng, B.
    Cui, L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 888 - 889
  • [37] Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis
    Druart, Charlotte
    El Sankari, Souraya
    van Pesch, Vincent
    PATIENT-RELATED OUTCOME MEASURES, 2018, 9 : 1 - 10
  • [38] An integrated candidate gene study of response to fingolimod in relapsing remitting multiple sclerosis patients
    Clarelli, F.
    Provero, P.
    Ferre, L.
    Mascia, E.
    Sferruzza, G.
    Radaelli, M.
    Moiola, L.
    Martinelli, V.
    Comi, G.
    Boneschi, F. Martinelli
    Esposito, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 188 - 189
  • [39] Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study
    Ilki, Canan Duman
    Gunduz, Tuncay
    Kurtuncu, Murat
    Yapici, Zuhal
    Sencer, Serra
    Eraksoy, Mefkure
    TURKISH JOURNAL OF NEUROLOGY, 2020, 26 (01) : 34 - 38
  • [40] Fingolimod A Review of its Use in the Management of Relapsing-Remitting Multiple Sclerosis
    Scott, Lesley J.
    CNS DRUGS, 2011, 25 (08) : 673 - 698
12345